Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).
Ziad Bakouny(Dana-Farber Cancer Institute), Toni K. Choueiri(Harvard University), Ronan Flippot(Institut Gustave Roussy), David F. McDermott(Beth Israel Deaconess Medical Center), Petra Ross‐Macdonald(Bristol-Myers Squibb (United States)), Gwo‐Shu Mary Lee(Dana-Farber Cancer Institute), Eliezer M. Van Allen(Dana-Farber Cancer Institute), Yue Hou(Inner Mongolia Medical University), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Sabina Signoretti(Brigham and Women's Hospital), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Abdallah Flaifel(Brigham and Women's Hospital), David A. Braun(Yale Cancer Center), Amin H. Nassar(Brigham and Women's Hospital), Sachet A. Shukla(The University of Texas MD Anderson Cancer Center), Xīn Gào(Massachusetts General Hospital), Yuko Ishii(Bristol-Myers Squibb (United States)), Sarah Abou Alaiwi(Yale New Haven Hospital), Daniel Yick Chin Heng(University of Calgary), Wenting Pan(Beijing University of Chemical Technology)
Cited by 5
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k